ZEALAND PHARMA AS
๐ฉ๐ฐDenmark
- Country
- ๐ฉ๐ฐDenmark
- Ownership
- -
- Established
- 1998-01-01
- Employees
- 150
- Market Cap
- $9.1B
Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 111
- Registration Number
- NCT02367053
- Locations
- ๐ฉ๐ช
Profil GmbH, Neuss, Germany
Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 591
- Registration Number
- NCT01977755
- Locations
- ๐ฉ๐ฐ
The Heart Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2010-11-02
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 66
- Registration Number
- NCT00868660
- Locations
- ๐บ๐ธ
CRI Worldwide, Willingboro, New Jersey, United States
ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2007-02-28
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 130
- Registration Number
- NCT00283361
- Locations
- ๐บ๐ธ
LAC-USC Medical Center-Division of Cardiology, Los Angeles, California, United States
๐บ๐ธUniversity of Maryland, Baltimore, Maryland, United States
๐บ๐ธHealth First Clinical Research Institute, Melbourne, Florida, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath